Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

Prior treatment

• patients with HLA-matched hematopoietic stem cell donors and willing to receive HLA-matched hematopoietic stem cell transplantation;
• patients having received thalidomide treatment within the past 3 months;
• patients having received any type of gene and/or cell therapy in the past;

Other illness

• patients with known infectious diseases such as hepatitis B, hepatitis C, AIDS, syphilis, human T-lymphotropic virus, etc.;
• patients with serious active bacterial, viral, fungal, malaria or parasitic infections;
• patients with autoimmune deficiency diseases;
• patients with a history of malignant tumors or current malignant tumors;
• patients with uncorrected bleeding disease;
• patients with severe mental illness (such as severe depression, schizophrenia, etc.) or cognitive dysfunction (dementia, delirium, etc.), which are unable to cooperate with the study;
• patients with severe allergies;

Lab values

• patients with important organ diseases or abnormal laboratory tests, including but not limited to: 1) patients with cirrhosis, liver fibrosis or active hepatitis, and/or abnormal liver function tests (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN; alkaline phosphatase ≥2.5×ULN); 2) patients with heart disease, or left ventricular ejection fraction (LVEF) \<60%, or severe iron deposition in the heart; 3) kidney disease, or blood creatinine ≥1.5×ULN with creatinine clearance \<30% of normal level; 4) patients with endocrine dysfunction;
• peripheral blood white blood cell (WBC) count \<3×10\^9/L or platelet count \<100×10\^9/L;

Other

• female patients who are pregnant, breastfeeding, or planning to become pregnant within 1 year of participating in this trial;
• patients who are participating in other clinical trials;
• other situations that are not suitable for participation in this clinical trial as assessed by the investigator.

• patients with transfusion-dependent thalassemia;
• patients who are planning to receive matched unrelated donor hematopoietic stem cell transplantation (MUD-HSCT) or HLA haploidentical donor hematopoietic stem cell transplantation (HID-HSCT);
• physical condition score (Lansky/Karnofsky score) ≥ 70%;
• patients (or legal guardians) voluntarily participate in the study and sign the informed consent form